| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1312 | |
| Phytochemical name or plant extracts | Red ginseng extract | |
| PMID | 27189791 | |
| Literature evidence | As a means of overcoming the drug resistance-mediated failure of paclitaxel chemotherapy, the potential of Korean red ginseng extract (KRG) as an adjuvant chemotherapy has been reported only in in vitro. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Extract | |
| Source of phytochemicals or plant Extracts | Korean red ginseng | |
| Geographical availability | Khabarovsk, Korea, Manchuria, Primorye | |
| Plant parts | Rhizome | |
| Other cancers | Breast cancer | |
| Target gene or protein | P-gp , Bax, Bak, BAD, Bcl-2, Bcl-xL, Fas, FasL | |
| Gene or Protein evidence | KRG inhibited P-gp protein expression and transcellular efflux of paclitaxel in MDCK-mdr1 cells, but KRG was not a substrate of P-gp ATPase. KRG extract increased the expression of pro-apoptotic proteins BAX, BAK, and BAD and decreased the expression of anti-apoptotic proteins Bcl-2 and Bcl-XL in both cells. The expressions of Fas and FasL were increased in lower doses, but decreased in higher doses in both cells. | |
| Target pathways | Induces extrinsic and intrinsic apoptotic pathways in MCF-7 breast cancer cells and MCF-10A non-malignant breast cells. | |
| IC50 | NA | |
| Potency | NA | |
| Cell line/ mice model | MCF-7, MCF-10A | |
| Additional information | KRG increased systemic circulation of oral paclitaxel and its distribution to tumors via P-gp inhibition in rats | |
| PubChem ID | NA | |
| Additional PMIDs | 33987910 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:91472-1 | |
| Safety | NA |